Ryan Haumschild, PharmD, MS, MBA: Welcome to this AJMC ® [The American Journal of Managed Care ®] program titled, “Generalized Pustular Psoriasis: Provider and Payer Considerations for Care.” I am Dr ...

You’ve probably heard of psoriasis—the chronic inflammatory condition that can cause itchy, scaly patches on your skin. Less well-known is a rare form of the disease called pustular psoriasis, which ...

GPP can be triggered by the initiation and withdrawal of various medications, in particular the withdrawal of corticosteroids, and by infections, stress, and other conditions. 1,5,6,10 Patients with a ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Steven R. Feldman, ...

Spevigo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 signaling. The Food and Drug Administration (FDA) has approved Spevigo ® (spesolimab-sbzo) for the treatment ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Spesolimab exhibited rapid control of generalized ...

The FDA has approved the monoclonal antibody spesolimab (Spevigo) as the first treatment for generalized pustular psoriasis (GPP), Boehringer Ingelheim announced. The approval stipulates use of the ...

An international consensus statement on generalized pustular psoriasis (GPP) from the International Psoriasis Council (IPC) includes the recommendation that considerations such as body surface area ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — Patients with generalized pustular psoriasis had a reduction in pustules and increased skin clearance ...

INGELHEIM, Germany--(BUSINESS WIRE)--EFFISAYIL ™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in ...

BRACKNELL, England--(BUSINESS WIRE)--Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II Effisayil TM 1 trial, which ...

If you’ve struggled with itchy, irritated skin, you’ve probably sought out various creams, lotions or ointments to treat it. But if you feel like you’ve tried everything and still suffer from dry and ...